GSK plc – Consensus Indicates Potential 45.7% Upside

Broker Ratings

GSK plc found using ticker (GSK) have now 3 analysts covering the stock. The analyst consensus points to a rating of ‘Buy’. The range between the high target price and low target price is between 63.75 and 57.42 calculating the mean target price we have 61.43. Now with the previous closing price of 42.16 this now indicates there is a potential upside of 45.7%. There is a 50 day moving average of 44.04 and the 200 moving average now moves to 44.5. The market capitalisation for the company is $86,472m. You can visit the company’s website by visiting: https://www.gsk.com

The potential market cap would be $125,996m based on the market concensus.

You can now share this on Stocktwits, just click the logo below and add the ticker in the text to be seen.

Share on Stocktwits

GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, HIV, immuno-inflammation, oncology, anti-viral, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterial, and dermatology. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories. The company offers its consumer healthcare products in the form of nasal sprays, tablets, syrups, lozenges, gum and trans-dermal patches, caplets, infant syrup drops, liquid filled suspension, wipes, gels, effervescents, toothpastes, toothbrushes, mouthwashes, denture adhesives and cleansers, topical creams and non-medicated patches, lip balm, gummies, and soft chews. It has collaboration agreements with 23andMe; Lyell Immunopharma; Novartis; Sanofi SA; Surface Oncology; Progentec Diagnostics; Alector; and CureVac AG., as well as strategic partnership with IDEAYA Biosciences and Vir Biotechnology The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.

You might also enjoy reading  GSK plc - Consensus Indicates Potential 70.5% Upside

Good news travels fast (but only if you make that happen). Share on:

Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on facebook
Facebook
Share on email
Email
Share on reddit
Reddit

AIM All Share Index